TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.

ABSTRACT: Chronic lymphocytic leukemia is associated with a highly heterogeneous disease course in terms of clinical outcomes and responses to chemoimmunotherapy. This heterogeneity is partly due to genetic aberrations identified in chronic lymphocytic leukemia cells such as mutations of TP53 and/or deletions in chromosome 17p [del(17p)], resulting in loss of one TP53 allele. These aberrations are associated with markedly decreased survival and predict impaired response to chemoimmunotherapy thus being among the strongest predictive markers guiding treatment decisions in chronic lymphocytic leukemia. Clinical trials demonstrate the importance of accurately testing for TP53 aberrations [both del(17p) and TP53 mutations] before each line of treatment to allow for appropriat

SUBMITTER: Campo E 

PROVIDER: S-EPMC6269313 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature